ArticleVaccines2021
Design of Alphavirus Virus-Like Particles Presenting Circumsporozoite Junctional Epitopes That Elicit Protection against Malaria.
Open access · goldAbstract read
In one paragraph
Article in Vaccines, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 22 citations in OpenAlex.
- Overcoming immunogenic gaps in malaria subunit vaccines by broadening CSP regions targeted.The Journal of experimental medicine · 2026Article
- Protective immunity against malaria by a nanoparticle CIS43-based junctional vaccine alone or in combination with R21.NPJ vaccines · 2026Article
- Engineering strategies and decision frameworks for virus-like particle-based vaccines against infectious diseases.Frontiers in microbiology · 2026Review
- mRNA delivery of circumsporozoite protein epitope-based malaria vaccines induces protection in a mouse model.NPJ vaccines · 2025Article
- Comparison of major, minor and junctional circumsporozoite protein epitopes for malaria vaccine design.NPJ vaccines · 2025Article
- Protective immunity against malaria by a nanoparticle CIS43-based junctional vaccine alone or in combination with R21.bioRxiv : the preprint server for biology · 2025Article
- Elicitation of liver-stage immunity by nanoparticle immunogens displaying P. falciparum CSP-derived antigens.NPJ vaccines · 2025Article
- Current perspectives on alphavirus encapsidation, assembly and budding.Frontiers in cellular and infection microbiology · 2025Review
- Monoclonal antibodies to the circumsporozoite proteins as an emerging tool for malaria prevention.Nature immunology · 2024Review
- In-silico analysis of potent Mosquirix vaccine adjuvant leads.Journal, genetic engineering & biotechnology · 2023Article
- Malaria therapeutics: are we close enough?Parasites & vectors · 2023Review
- Humoral Immune Responses toInfection and drug resistance · 2023Review
- Live Vaccination with Blood-StageVaccines · 2022Article
- A vaccine targeting the L9 epitope of the malaria circumsporozoite protein confers protection from blood-stage infection in a mouse challenge model.NPJ vaccines · 2022Article
- The light chain of the L9 antibody is critical for binding circumsporozoite protein minor repeats and preventing malaria.Cell reports · 2022Article
- How to induce protective humoral immunity against Plasmodium falciparum circumsporozoite protein.The Journal of experimental medicine · 2022Review
- How promising are HIV-1-based virus-like particles for medical applications.Frontiers in cellular and infection microbiology · 2022Review
- Vaccination in a humanized mouse model elicits highly protective PfCSP-targeting anti-malarial antibodies.Immunity · 2021Article
- A Monoclonal Antibody for Malaria Prevention.The New England journal of medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors at 4 institutions in 1 country.
Joseph R FrancicaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Wei ShiVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Gwo-Yu ChuangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Steven J ChenVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Lais Da Silva PereiraVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
S Katie FarneyVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0002-8785-8039
Barbara J FlynnVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Li OuVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Tyler StephensElectron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21701, USA.
Yaroslav TsybovskyElectron Microscopy Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research Sponsored by the National Cancer Institute, Frederick, MD 21701, USA.
Lawrence T WangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Alexander AndersonLaboratory of Adjuvant & Antigen Research, US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Zoltan BeckLaboratory of Adjuvant & Antigen Research, US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Marlon DillonVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Azza H IdrisVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-1847-5488
Nicholas HurlburtVaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA.ORCID 0000-0001-9891-916X
Tracy LiuVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Baoshan ZhangVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Carl R AlvingLaboratory of Adjuvant & Antigen Research, US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.ORCID 0000-0002-1913-3909
Gary R MatyasLaboratory of Adjuvant & Antigen Research, US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, MD 20910, USA.
Marie PanceraVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
John R MascolaVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
Peter D KwongVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.ORCID 0000-0003-3560-232X
Robert A SederVaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
National Institutes of Health · USWalter Reed Army Institute of Research · USFrederick National Laboratory for Cancer Research · USFred Hutch Cancer Center · US
Funding
Design Of ImmunogensZIAAI005024 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI ZHOU, TONGQING · 2009 to 2025
$21.5MDevelopment of Pre-Erythrocytic Malaria Vaccines and antibodiesZIAAI005107 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI SEDER, ROBERT A · 2010 to 2025
$20.7MRational Immunogen Design Using Computational MethodsZICAI005114 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI RAWI, REDA · 2010 to 2025
$4.3MVaccine Research Center ZIA AI005024-19
Abstract
The most advanced malaria vaccine, RTS,S, includes the central repeat and C-terminal domains of the
Indexed as
junctional epitopemalarianeutralizing antibodiesparasitePlasmodium falciparumvaccinesvirus-like particle
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.